Faisal Zain is a distinguished authority in medical technology and biopharmaceutical manufacturing, known for his deep expertise in the logistical and technical hurdles of cell-based treatments. As a strategist who has seen the evolution of diagnostics and therapeutics from the laboratory bench to
The ability to identify a lethal tumor through a single vial of blood has long been considered the holy grail of oncology, moving the medical community closer to a future where reactive treatment is replaced by proactive prevention. At the center of this movement is Grail’s Galleri test, a m
A New Contender Enters the Ring for Vision Treatment For millions living with the wet form of age-related macular degeneration (wet AMD), the prospect of frequent, invasive eye injections is a burdensome reality. The landscape of treatment has long been dominated by effective but demanding
A Surprising Setback: FDA's Unexpected Rejection Jolts Disc Medicine and Patient Community In a significant blow to Disc Medicine and the patient community it serves, the U.S. Food and Drug Administration (FDA) has officially rejected the company's application for bitopertin, a novel drug
With his extensive background in medical technology and a deep focus on driving innovation, Faisal Zain has become a leading voice in the application of value-based care to solve some of healthcare’s most persistent challenges. Today, we'll delve into his insights on transforming care for c
Introduction: Assessing a New Oral Therapy for Achondroplasia For families navigating the complexities of achondroplasia, the prospect of replacing daily or weekly injections with a simple pill represents a profound shift in the treatment paradigm. This review evaluates the potential of
